Asset Details
Do you wish to reserve the book?
Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD
Do you wish to request the book?
Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD
2001
Overview
β2-Adrenergic agonists are commonly used asbronchodilators to treat patients with COPD. In addition to prolongedbronchodilation, long-acting β2-agonists (LABAs) exertother effects that may be of clinical relevance. These includeinhibition of airway smooth-muscle cell proliferation and inflammatorymediator release, as well as nonsmooth-muscle effects, such asstimulation of mucociliary transport, cytoprotection of the respiratorymucosa, and attenuation of neutrophil recruitment and activation. Thisreview details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.
Publisher
Elsevier Inc,American College of Chest Physicians
